Adverse effects of platinum agents in patients with ovarian cancer

• In: Hospital Pharmacy Posters
• At: Lisbon (Portugal) (2010)
• Type: Poster
• Poster code: HPS-P-055
• By: MIRACI, Mirela (Department of Pharmacy, University of Tirana,, Tirana, Albania)
• Co-author(s): Tarifa, Dhurata (Service of Oncology, Department of Chemotherapy, TIRANA, Albania)
  Ademi, Sabo (Service of Oncology, Department of Chemotherapy, TIRANA, Albania)
  Toska, Vilma (Department of Pharmacy, University of Tirana,, TIRANA, Albania)
  Kellici, Suela (Department of Pharmacy, University of Tirana,, TIRANA, Albania)
  
• Abstract:

  Introduction: Introduction of cisplatin and carboplatin at the most ovarian cancer at stage III or IV, improves survival. Cisplatin is an inorganic heavy metal complex that has activity of a cell-cycle-phase-nonspecific alkylating agent. It produces interstrand and intrastrand DNA cross-links and forms DNA adducts, thereby inhibiting the synthesis

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login